AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05390008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Pilates Exercise
Description: Before starting the 12-week practice protocol, the concept of stabilization was explained to the participants. Participants were taught how to control the core region by using the stabilizer device and the basic principles of pilates. The exercise program was planned that would last 50 minutes. This program was carried out as three-stage and these stages were warm-up phase, main exercise program and cool down phase. The allocated times for the warm-up phase was 10 minutes. The allocated time for the main exercise program was 30 minutes and active resting was done by performing breathing exercises in the 15th minute of the main exercise program. The allocated time for the cool down phase was 10 minutes. Each exercise was done as 10 repetitions then the next exercise was started.~The exercises of the second 6 weeks were performed by adding a red elastic exercise band at the beginner-intermediate level, which released 1.7 kg force with 100% stretching.
Study NCT04424147 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HVA Regimens as Salvage Treatment
Description: venetoclax with a dose of 400mg per day for 14 days, combined with azacitidine (AZA) with a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days
Study NCT02427854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education by animated training video
Description: Training performed by watching an animated educational video.
Study NCT02427854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interactive hands-on bedside training
Description: Training performed as a traditional bedside training supported by a trainer in person.
Study NCT00419757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol (SYMBICORT) pMDI
Description: SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
Study NCT00419757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide HFA pMDI
Description: Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
Study NCT01842269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil 500mg
Study NCT01842269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil 250mg
Study NCT01726296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
Study NCT01726296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Description: Complete patient medical chart audit
Study NCT03983408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng
Description: Participants are provided with 2 Korean Red Ginseng extract tablets twice a day for total 24 weeks.
Study NCT03983408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets. Participants are parovided with 2 placebo tablets twice a day for first 12 weeks, following Korean Red Ginseng extract tablets twice a day for another 12 weeks.
Study NCT02843009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise Training
Description: Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl
Study NCT02843009 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise Training
Description: Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl
Study NCT02843009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation
Description: Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
Study NCT02843009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplementation
Description: Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
Study NCT02305602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VentriGel
Description: VentriGel will be injected via MyoStar catheter after NOGA mapping
Study NCT03360448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad5.hAC6
Description: 1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
Study NCT03360448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
Study NCT02654652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment
Study NCT02654652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment
Study NCT03381339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillating rotating power toothbrush
Description: a battery powered oscillating rotating toothbrush will be used for twice daily regular home dental hygiene
Study NCT03704168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYOABLATION
Description: The SeedNet® System induces freezing and thawing at the tip of the needle. These freezing and thawing processes are based on the Joule-Thomson effect. The unique technology of the SeedNet® System provides extremely rapid freeze and thaw operations. The system's software controls the flow of gases from the gas sources, through the manifold, to the needle and probe tips. The system can immediately switch from the freezing process to the thawing process, after which the needle can be released. This device is an FDA-cleared medical device. This IDE application is to allow for use of the commercially available device in a new clinical indication, namely cryoablation of the submandibular glands.
Study NCT01623193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All-blood cardioplegia
Description: The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
Study NCT01623193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardioplegia
Description: This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
Study NCT04224402 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mFOLFORINOX
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study NCT00283244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: given orally
Study NCT00283244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: given IV
Study NCT00283244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given IV
Study NCT02628028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally
Study NCT02628028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03242967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral tablet
Study NCT03242967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: subcutaneous or intravenous
Study NCT02731144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptamen intense
Study NCT02731144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novasource senior
Study NCT00494520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Errorful training condition
Description: Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended.
Study NCT00494520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Errorless training condition
Description: Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended.
Study NCT03172598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 low dose
Description: Capsule
Study NCT00673621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin Inhalation Powder
Description: 3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
Study NCT00673621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (Albuterol)
Description: 2 puff = 200 mcg total dose
Study NCT00673621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine chloride
Description: 5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
Study NCT00785811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine aspartate (Targifor)
Description: 3g of L-arginine taken orally in a single daily dose for 8 weeks
Study NCT00785811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo L-arginine aspartate (Targifor)
Description: Placebo of L-arginine taken orally in a single daily dose for 8 weeks
Study NCT02302170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H. pylori vaccine
Study NCT02302170 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02352519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UGBRSB
Description: Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
Study NCT02352519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration
Description: In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision
Study NCT00315991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Glucose Awareness Training for Parents
Study NCT02290080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: see arm description
Study NCT00438672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Injection
Description: Injection without steroid
Study NCT00438672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid (dexamethasone) Injection
Description: Injection with steroid (dexamethasone)
Study NCT01035567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid revascularization
Description: First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
Study NCT01035567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Grafting
Description: Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
Study NCT02409524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloVax
Description: Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)
Study NCT02409524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim (ID) injection AlloStim (IV) infusion
Study NCT02409524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRCL
Description: Autologous tumor-derived chaperone protein mixture
Study NCT03203187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: 330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening
Study NCT03203187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No mango intake for two weeks.
Study NCT02929277 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires
Study NCT04851353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GT+VC
Description: Gentle touch and verbal comfort,
Study NCT04851353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GT+VC
Description: Gentle touch and verbal comfort,
Study NCT04851353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smell
Description: Smell breast milk
Study NCT04851353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste
Description: Taste breast milk
Study NCT03453853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Loop Cerclage Annuloplasty
Description: Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty
Study NCT02856100 — intervention group
Intervention type: DRUG
Intervention: 18F DCFPyL- Radiopharmaceutical
Study NCT01941147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed ELF-MF
Description: (75 Hz, 1,8 mT)
Study NCT00710905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3
Description: Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
Study NCT04944745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: Moderate pressure manual treatment to the pectoral fascia.
Study NCT04944745 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Soft-touch Control
Description: No pressure manual treatment to the pectoral fascia.
Study NCT04765332 — intervention group
Intervention type: OTHER
Intervention: DLQI and PSO-TARGET QoL grid
Description: At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid
Study NCT02957032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2
Description: All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles.
Study NCT02957032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
Study NCT03545802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-HIT
Description: Participants completed 6 weeks of home-based high-intensity interval training 3 times per week
Study NCT00518895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine plus Genasense
Description: Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
Study NCT00518895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine plus placebo
Description: Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
Study NCT01147536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Study NCT03636529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart cherry juice
Description: Participants randomized to consume for 4-weeks either placebo beverage or single-strength tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage for 4 weeks to account for timing and order effects.
Study NCT03636529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
Study NCT04311710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified Dose on Specified Days
Study NCT04311710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified Days
Study NCT04311710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENHANZE (rHuPH20)
Description: Specified Dose on Specified Days
Study NCT00490152 — intervention group
Intervention type: BEHAVIORAL
Intervention: Automated diary system
Description: Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study.
Study NCT04668040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: Muscle energy technique for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of contraction was 10 sec, rest interval was 5 sec, stretch duration was 30 sec, number of repetition of stretch was 5, number of set was 1, frequency per week was 3
Study NCT04668040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching exercises for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of stretch was 15 sec, rest interval was 5 sec, number of repetition was 5, number of set was 1, frequency per week was 3
Study NCT00558077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus clomiphene citrate
Description: Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
Study NCT00558077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian drilling
Description: Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
Study NCT03435302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Plus Cisplatin
Description: Temozolomide is the oral analog of dacarbazine (DTIC), shows potential advantages over dacarbazine.~Cisplatin is an agent that can potentially enhance the activity of temozolomide.
Study NCT03435302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose IFN-a2b
Description: Interferon belongs to the large class of glycoproteins known as cytokines.
Study NCT03172598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 middle dose
Description: Capsule
Study NCT03172598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 high dose
Description: Capsule
Study NCT03172598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule